Patents by Inventor Richard J. Traystman

Richard J. Traystman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage form of L-Methionine S-Sulfoximine
    Patent number: 6875792
    Abstract: Methods for the treatment of both diseases susceptible to the inhibition of mammalian glutamine synthetase and progressive hyperammonemic encephalopathy comprising administering L-methionine S-sulfoxime at a dose not to exceed 10 mg/kg body weight are disclosed. Preferably, the dose should not exceed 8 mg/kg; more preferably, the dose should not exceed 5 mg/kg; most preferably, the dose should not exceed 2.5 mg/kg.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: April 5, 2005
    Assignee: MSO Pharma LLC
    Inventors: Saul Brusilow, Richard J. Traystman, Raymond C. Koehler
  • Novel dosage form of L-Methionine S-Sulfoximine
    Publication number: 20030144357
    Abstract: A novel dosage form of L-Methionine S-Sulfoximine for the treatment of diseases and conditions susceptible to the inhibition of glutamine synthetase is disclosed. The novel dosage form should not exceed 10 mg/kg by body weight over a one week period, and preferably should not exceed 8 mg/kg, and more preferably should not exceed 5 mg/kg, and most preferably should not exceed 2.5 mg/kg.
    Type: Application
    Filed: January 31, 2002
    Publication date: July 31, 2003
    Inventors: Saul Brusilow, Richard J. Traystman, Raymond C. Koehler
  • Method of using selective parp inhibitors to prevent or treat neurotoxicity
    Patent number: 6358975
    Abstract: Neutral tissue damage resulting for ischemia and reperfusion injury or neurodegenerative diseases can be prevented by administering therapeutically effective amounts of certain selective inhibitors of poly(ADP-ribose)polymerase. The inhibitors can be administered intravenously, intraperitoneally, intramuscularly, intraventricularly, or orally. They can be administered as a capsule or tablet containing single or divided dose. Alternatively, the inhibitors can be administered as a sterile solution, suspension or emulsion.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: March 19, 2002
    Assignee: Johns Hopkins University
    Inventors: Mikael J. Eliasson, Kenji Sampei, Allen S. Mandir, Patricia D. Hurn, Richard J. Traystman, Jun Bao, Andrew Pieper, Ted M. Dawson, Solomon Snyder, Valina L. Dawson